A review of ovarian cancer screening

published_or_final_versio

The potential molecular therapeutic approach in targeting ovarian clear cell carcinoma

EditorialOvarian Clear Cell Carcinoma (OCCC) is a distinctive subtype of Epithelial Ovarian Cancer (EOC). Compared with other subtypes of EOC, CCC has relatively poor in prognosis and bad outcome in current clinical management using maximal cytoreduction and platinum plus paclitaxel–based combined chemotherapy. Therefore, the investigation of molecular therapeutic approaches targeting at signaling pathways associated with chemoresistance is needed. This review describes some recent potential signaling pathway targets and also suggests putative small molecule kinase inhibitors as well as natural anti-cancer agents in combating this disease.published_or_final_versio

The prognostic and therapeutic potential of AMP-activated protein kinase in ovarian cancer

Topics 3 - Translational Research for Ovarian Cancer: no. 3-2Ovarian cancer is one of the leading causes of cancer-associated death in women. The high mortality is due to its poor prognosis as most cases are found in late stages. Therefore, searching reliable tumor markers is urgently needed for clinical management of this disease. Altered cellular metabolism is a crucial phenomenon for the development and progression of ovarian cancer. AMP-activated protein kinase (AMPK) acts as a key intracellular energy sensor and regulator for governing energy balance homeostasis. It also closely links with cancer cell metabolism. Others and we have reported that the activation of AMPK by pharmacological agents shows cytotoxicity to cancer cells, indicating that targeting AMPK could be a promising therapeutic approach. On the other hand, our study also demonstrated that the AMPK activity had an inversely correlation between tumor stage and/or high grade ovarian cancer. Import...postprin

Cervical cancer screening

In Hong Kong, cervical cancer is the 4th commonest malignancy in females. Cervical cytology screening is effective in reducing the incidence and mortality of cervical cancer. Women should have regular cervical smears from the time they start to have sexual activity until they reach the age of 65. A cervical smear should be taken and handled properly, so that the sensitivity of the test will not be affected by the quality of the smear. Most of the laboratories in Hong Kong are now using the Bethesda System to report cervical smears. In order to manage patients properly, doctors should be familiar with this classification.published_or_final_versio

The role of serum tumour markers in gynaecological cancers

published_or_final_versio

Mechanisms of Chemoresistance in Human Ovarian Cancer at a Glance

published_or_final_versio

Preventing cervical cancer: primary and secondary measures

published_or_final_versio

Cervical cancer screening by enhanced cytology: application of novel markers

published_or_final_versio

Current concepts in the management of endometrial carcinoma

published_or_final_versio

Assessment of cell proliferation in hydatidiform mole using monoclonal antibody MIB1 to Ki-67 antigen

Aims - To assess the role of Ki67 immunoreactivity in predicting the clinical progress of hydatidiform mole. Methods - Tissue from 87 hydatidiform moles, 11 normal first trimester placentas, 11 normal term placentas and 17 spontaneous abortions were examined for expression of Ki67 antigen, using the monoclonal antibody MIB1. Results - Ki67 immunoreactivity was significantly higher in the tissue from normal first trimester placentas than in that from normal term placentas and spontaneous abortions. Among the 87 patients with hydatidiform moles studied, 20 developed persistent gestational trophoblastic disease and required subsequent treatment. There was no statistically significant difference in the Ki67 index between the 20 patients who developed persistent disease and those who did not. Conclusion-Hydatidiform moles which give rise to persistent trophoblastic disease do not have a higher proliferative rate than those which do not. The Ki67 index is not useful for predicting the prognosis of molar pregnancies.published_or_final_versio